Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Yonatan Erez, Eihab Ghantous, Aviel Shetrit, Ryan S Zamanzadeh, David Zahler, Yoav Granot, Orly Ran Sapir, Michal Laufer Perl, Shmuel Banai, Yan Topilsky, Ofer Havakuk
AIMS: The study aims to investigate exercise-limiting factors in hypertrophic cardiomyopathy (HCM) using combined stress echocardiography and cardiopulmonary exercise test. METHODS AND RESULTS: A symptom-limited ramp bicycle exercise test was performed in the semi-supine position on a tilting dedicated ergometer. Echocardiographic images were obtained concurrently with gas exchange measurements along predefined stages of exercise. Oxygen extraction was calculated using the Fick equation at each activity level...
April 18, 2024: ESC Heart Failure
#2
JOURNAL ARTICLE
Muhammad Usman Almani, Khawaja Muhammad Talha, Laibah Arhsad Khan, Ishaque Hameed, Zain Ul Abideen Asad, Marat Fudim, Richard Krasuski, Muhammad Shahzeb Khan
Atrial fibrillation/flutter (AF) is the most common dysrhythmia in patients with hypertrophic cardiomyopathy (HCM). Unexplained left ventricular hypertrophy and left ventricular outflow tract (LVOT) obstruction are integral components of HCM pathology which can cause increased left atrial pressure and atrial myopathy contributing to the substrate for AF. Our aim was to determine the impact of AF on hospital readmissions in patients with HCM. We conducted a retrospective analysis using the 2015 - 2019 Nationwide Readmission Database to analyze the effect of AF on 30-day readmission and causes of 30-day readmission in patients with HCM...
April 16, 2024: American Journal of Cardiology
#3
JOURNAL ARTICLE
Matteo Castrichini, Said Alsidawi, Jeffrey B Geske, Darrell B Newman, Adelaide M Arruda-Olson, J Martijn Bos, Steve R Ommen, Konstantinos C Siontis, Michael J Ackerman, John R Giudicessi
No abstract text is available yet for this article.
April 13, 2024: Heart Rhythm: the Official Journal of the Heart Rhythm Society
#4
JOURNAL ARTICLE
Shengwei Wang, Ke Zhang, Meng He, Hongchang Guo, Hao Cui, Shuiyun Wang, Yongqiang Lai
AIMS: Type 2 diabetes (T2D), a prevalent cardiovascular disease, is linked with cardiac arrhythmias such as atrial fibrillation (AF) and ventricular arrhythmia. This study evaluated T2D's impact on these arrhythmias in patients with obstructive hypertrophic cardiomyopathy (OHCM). METHODS AND MATERIALS: We retrospectively analyzed the data of 75 patients with OHCM and T2D from two medical centers in China from 2011 to 2020. A propensity score-matched cohort of 150 patients without T2D was also analyzed...
March 27, 2024: Diabetes & Metabolic Syndrome
#5
JOURNAL ARTICLE
Nawin L Ramdat Misier, Jorik H Amesz, Yannick J H J Taverne, Hoang Nguyen, Mathijs S van Schie, Paul Knops, Arend F L Schinkel, Peter L de Jong, Bianca J J M Brundel, Natasja M S de Groot
BACKGROUND: Atrial fibrillation (AF) in patients with hypertrophic obstructive cardiomyopathy (HOCM) may be caused by a primary atrial myopathy. Whether HOCM-related atrial myopathy affects mainly electrophysiological properties of the left atrium (LA) or also the right atrium (RA) has never been investigated. OBJECTIVE: To characterize atrial conduction and explore differences in the prevalence of conduction disorders, potential fractionation, and low voltage areas (LVA) between the RA and LA during sinus rhythm (SR) as indicators of potential arrhythmogenic areas...
January 19, 2024: Heart Rhythm: the Official Journal of the Heart Rhythm Society
#6
JOURNAL ARTICLE
Florian Rader, Artur Oręziak, Lubna Choudhury, Sara Saberi, David Fermin, Matthew T Wheeler, Theodore P Abraham, Pablo Garcia-Pavia, Donna R Zwas, Ahmad Masri, Anjali Owens, Sheila M Hegde, Tim Seidler, Shawna Fox, Ganesh Balaratnam, Amy J Sehnert, Iacopo Olivotto
BACKGROUND: Data assessing the long-term safety and efficacy of mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy are needed. OBJECTIVES: The authors sought to evaluate interim results from the EXPLORER-Long Term Extension (LTE) cohort of MAVA-LTE (A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed EXPLORER-HCM; NCT03723655). METHODS: After mavacamten or placebo withdrawal at the end of the parent EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT03470545), patients could enroll in MAVA-LTE...
January 2024: JACC. Heart Failure
#7
JOURNAL ARTICLE
Edoardo Bertero, Chiara Chiti, Maria Alessandra Schiavo, Giacomo Tini, Paolo Costa, Giancarlo Todiere, Barbara Mabritto, Lorenzo-Lupo Dei, Alessia Giannattasio, Davide Mariani, Carla Lofiego, Caterina Santolamazza, Emanuele Monda, Giovanni Quarta, Davide Barbisan, Giulia Elena Mandoli, Massimo Mapelli, Maurizio Sguazzotti, Francesco Negri, Simona De Vecchi, Michele Ciabatti, Daniela Tomasoni, Andrea Mazzanti, Francesca Marzo, Cesare de Gregorio, Claudia Raineri, Pier Filippo Vianello, Alberto Marchi, Giulia Biagioni, Eleonora Insinna, Vanda Parisi, Raffaello Ditaranto, Andrea Barison, Andrea Giammarresi, Gaetano Maria De Ferrari, Silvia Priori, Marco Metra, Maurizio Pieroni, Giuseppe Patti, Massimo Imazio, Enrica Perugini, Piergiuseppe Agostoni, Matteo Cameli, Marco Merlo, Gianfranco Sinagra, Michele Senni, Giuseppe Limongelli, Enrico Ammirati, Fabio Vagnarelli, Lia Crotti, Luigi Badano, Chiara Calore, Domenico Gabrielli, Federica Re, Giuseppe Musumeci, Michele Emdin, Emanuele Barbato, Beatrice Musumeci, Camillo Autore, Elena Biagini, Italo Porto, Iacopo Olivotto, Marco Canepa
AIMS: In the EXPLORER-HCM trial, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved functional capacity of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients. We sought to define the potential use of mavacamten by comparing real-world HOCM patients with those enrolled in EXPLORER-HCM and assessing their eligibility to treatment. METHODS AND RESULTS: We collected information on HOCM patients followed up at 25 Italian HCM outpatient clinics and with significant LVOTO (i...
December 22, 2023: European Journal of Heart Failure
#8
Jassin Hamidi, Joachim Winter, Rene Weber, Sven Dittmann, Eric Schulze-Bahr
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a serious hereditary cardiomyopathy. It is characterized morphologically by an increased left ventricular wall thickness and mass and functionally by enhanced global chamber function and myocellular contractility, diastolic dysfunction, and myocardial fibrosis development. Typically, patients with HCM experience atrial fibrillation (AF), syncope, and ventricular fibrillation (VF), causing severe symptoms and cardiac arrest. In contrast, sinoatrial node (SAN) arrest in the setting of HCM is uncommon...
2023: Frontiers in Cardiovascular Medicine
#9
JOURNAL ARTICLE
Kirolos Barssoum, Abd Elrahman Abo Moad, Medhat Chowdhury, Ankit Agrawal, Ramy AbdelMassih, Sarathlal Renjithlal, Ahmed H Mohamed, Majd Alhuarrat, Claudine Abdou, Mohamed Saleh, Rama Ellauzi, Wissam Khalife, Devesh Rai, Khaled Chatila, Hani Jneid
BACKGROUND: Data regarding hypertrophic obstructive cardiomyopathy (HOCM) patients undergoing noncardiac surgery is lacking. We sought to examine the perioperative outcomes of HOCM patients undergoing noncardiac surgery using a national database. METHODS: We used the National readmission database from 2016 to 2019. We identified HOCM, heart undergoing noncardiac surgery using ICD 10 codes. We examined hospital outcomes as well as 90 days readmission outcomes...
November 16, 2023: International Journal of Cardiology
#10
J Novo Matos, J Silva, S Regada, S Rizzo, M Serena Beato, C Basso
A seven-year-old female neutered Parson Russel Terrier was referred for syncopal episodes. An electrocardiogram revealed paroxysmal atrial flutter followed by periods of sinus arrest, suggesting sick sinus syndrome. Echocardiography showed severe biventricular wall thickening (hypertrophic cardiomyopathy (HCM) phenotype) with no signs of fixed or dynamic left ventricular outflow tract obstruction. Blood pressure, abdominal ultrasound, serum total thyroxin and thyroid-stimulating hormone, and insulin-like growth factor-1 were all within normal limits...
October 16, 2023: Journal of Veterinary Cardiology: the Official Journal of the European Society of Veterinary Cardiology
#11
JOURNAL ARTICLE
Maria Angela Losi, Emanuele Monda, Raffaella Lombardi, Michele Lioncino, Grazia Canciello, Marta Rubino, Gaetano Todde, Martina Caiazza, Felice Borrelli, Adelaide Fusco, Annapaola Cirillo, Errico Federico Perillo, Joseph Sepe, Daniela Pacella, Giovanni de Simone, Paolo Calabro, Giovanni Esposito, Giuseppe Limongelli
BACKGROUND AND AIM: Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) with significant effects on outcome. We aim to compare the left atrial (LA) diameter measurement with HCM-AF Score in predicting atrial fibrillation (AF) development in HCM. METHODS: From the regional cohort of the Campania Region, Italy, 519 HCM patients (38% women, age 45 ± 17 years) without history of AF, were enrolled in the study...
November 9, 2023: International Journal of Cardiology
#12
REVIEW
Ernesto Calderon Martinez, Nancy Y Ortiz-Garcia, Domenica A Herrera Hernandez, David Arriaga Escamilla, Diana L Diaz Mendoza, Diana Othon Martinez, Luz M Ramirez, Jonathan Reyes-Rivera, Jinal Choudhari, George Michel
Hypertrophic cardiomyopathy (HCM) is a hereditary cardiac condition characterized by unexplained left ventricular hypertrophy without a hemodynamic cause. This condition is prevalent in the United States, resulting in various clinical manifestations, including diastolic dysfunction, left ventricular outflow obstruction, cardiac ischemia, and atrial fibrillation. HCM is associated with several genetic mutations, with sarcomeric mutations being the most common and contributing to a more complex disease course...
October 2023: Curēus
#13
JOURNAL ARTICLE
Yan Wang, Weihua Gao, Xu Han, Jenny Jiang, Belinda Sandler, Xiaoyan Li, Carla Zema
AIMS: Assess the relationship between New York Heart Association (NYHA) functional class and cardiovascular (CV) outcomes in obstructive hypertrophic cardiomyopathy (HCM). MATERIALS AND METHODS: This retrospective cohort study used the Optum Market Clarity database with linked claims and electronic health records. Adults (aged ≥18 years) with obstructive HCM and ≥1 NYHA class assessment after first HCM diagnosis were eligible (selection period: 2007-2021)...
October 30, 2023: Journal of Medical Economics
#14
JOURNAL ARTICLE
Milorad Tesic, Lazar Travica, Vojislav Giga, Ivana Jovanovic, Danijela Trifunovic Zamaklar, Dejana Popovic, Djordje Mladenovic, Marija Radomirovic, Jelena Vratonjic, Nikola Boskovic, Srdjan Dedic, Olga Nedeljkovic Arsenovic, Srdjan Aleksandric, Stefan Juricic, Branko Beleslin, Ana Djordjevic Dikic
Background and Objectives : Mitral valve pathology and mitral regurgitation (MR) are very common in patients with hypertrophic cardiomyopathy (HCM), and the evaluation of mitral valve anatomy and degree of MR is important in patients with HCM. The aim of our study was to examine the potential influence of moderate or moderately severe MR on the prognosis, clinical presentation, and structural characteristics of HCM patients. Materials and Methods : A prospective study examined 176 patients diagnosed with primary asymmetric HCM...
October 9, 2023: Medicina
#15
Christine Henen, Elise A Johnson, Sergio Sokol
Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic cardiovascular disorder characterized by the thickening of the heart muscle, particularly the left ventricle. It is a leading cause of sudden cardiac death in young individuals. HOCM is associated with various complications, including arrhythmias and an increased risk of stroke. Patients with HOCM are at an increased risk of stroke due to the development of atrial fibrillation (AFib), a common arrhythmia observed in HOCM. AFib can result in the formation of blood clots in the atria, which may subsequently embolize the brain, causing a stroke...
October 2023: Curēus
#16
JOURNAL ARTICLE
Onur Akhan, Mehmet Kis, Tuncay Guzel, Mustafa Dogdus, Mehdi Zoghi
INTRODUCTION: Hypertrophic cardiomyopathy(HCM) is a genetic cardiomyopathy with a prevalence of 1/500 and causes adverse outcomes, usually due to left ventricular outflow tract obstruction. AIM: In this study, we aimed to determine the possible differences and predictors of obstructive hypertrophic cardiomyopathy HCM (Obs-HCM) and nonobstructive HCM (Nonobs-HCM) by electrocardiographic (ECG) and echocardiographic (ECHO) evaluations with clinical, demographic, and biochemical characteristics...
October 9, 2023: Acta Cardiologica
#17
REVIEW
Zachariah Nealy, Christopher Kramer
A multimodality imaging evaluation in hypertrophic cardiomyopathy is often used for risk stratification. Recent developments in imaging have allowed for better diagnosis, prognosis, and decision-making for a variety of therapies from medical to interventional. Echocardiography and magnetic resonance have been integral in evaluating subtype, left ventricular function, tissue characterization, left atrial measurements, valvular function, and presence of left ventricular aneurysm and outflow tract obstruction...
October 2023: Heart Failure Clinics
#18
JOURNAL ARTICLE
Changpeng Song, Jingang Cui, Xinxin Zheng, Jie Lu, Xinli Guo, Shuiyun Wang, Xiaohong Huang
Obstructive hypertrophic cardiomyopathy (oHCM) and mitral valve (MV) prolapse (MVP) are the 2 conditions which could cause symptomatic heart failure and sudden cardiac death. The clinical characteristics and surgical outcomes of patients with oHCM and MVP have not been well reported. From April 2012 to February 2018, 84 patients with oHCM (28 patients with MVP and 56 gender- and age-matched patients without MVP) who underwent septal myectomy at our institution were enrolled in this study. Information on clinical characteristics and outcomes was obtained from electronic medical records and follow-up surveys...
September 12, 2023: American Journal of Cardiology
#19
JOURNAL ARTICLE
Christopher Ryan Zörner, Jannik Pallisgaard, Anne-Marie Schjerning, Morten Kvistholm Jensen, Jacob Tønnesen, Lise Da Riis-Vestergaard, Charlotte Middelfart, Peter Vibe Rasmussen, Gunnar Gislason, Morten Lock Hansen
OBJECTIVES: To describe the population of patients diagnosed with hypertrophic cardiomyopathy (HCM) in Denmark and determine temporal trends in incidence and patient characteristics over time. DESIGN: Nationwide retrospective cohort study. SETTING: Danish nationwide administrative and clinical registers and databases. PARTICIPANTS: All patients aged ≥16 years diagnosed with HCM from 2005 to 2018. OUTCOMES MEASURES: Time trends in HCM diagnosis, patient characteristics, comorbidities and pharmacotherapy were identified and tested for significance using the Cochran-Armitage trend test...
September 4, 2023: BMJ Open
#20
REVIEW
Daniel Bishev, Stephanie Fabara, Isaac Loseke, Akankcha Alok, Hashim Al-Ani, Yvette Bazikian
BACKGROUND: Current pharmacological options for hypertrophic cardiomyopathy (HCM) are not disease-specific; while it treats symptoms, mavacamten targets the underlying pathology. We aim to assess the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic obstructive HCM. METHODS: This systematic review of the literature followed the PRISMA guidelines. Title/abstract and topics were searched using the following term: "mavacamten"...
July 14, 2023: Heart, Lung & Circulation
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
